



*This work is supported through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-1505-30497).*

Hello!

As members of the Patient Leadership Team, we have worked to keep patients at the center of the COMET Study (AFT-25) from the beginning. Now, we invite you to learn about the study, and consider why you may want to join.

***Why do we believe this clinical trial is important?***

For many years, different grades of ductal carcinoma in situ (DCIS) were all treated the same. This included immediate surgery (with or without radiation), and sometimes endocrine (hormone-blocking) therapy in pill form. Newer studies have questioned whether some women with low-risk DCIS might do just as well if they were followed closely instead. This is called “active surveillance” or “active monitoring.”

COMET stands for “Comparison of Operative to Monitoring and Endocrine Therapy for low-risk DCIS.” The COMET Study compares women on active surveillance to those who have immediate surgery. Endocrine (hormone-blocking) therapy includes pills that block hormones, and is optional for both study groups. It is not necessarily a requirement for women in the active surveillance group. The results may help researchers, doctors and patients better understand low-risk DCIS and if active surveillance has similar outcomes to immediate surgery. If you decide to join the COMET Study, your health will be carefully checked over the five years you are on the study.

Women who join the COMET study will help us learn more about DCIS. By completing the patient survey at the start of the study and again at regular intervals throughout the study, you will share your experience in ways that doctors are not always aware of. This information may help other women like you when they face a DCIS diagnosis.

The website, [www.DCISoptions.org](http://www.DCISoptions.org) has information about the COMET Study as well as DCIS in general. It includes interviews with the COMET Study project team, new progress in DCIS research, and support materials for making decisions. There is also a list of frequently asked questions that may be helpful. If you want to learn more, or think you may want to join the COMET study, please talk with your doctor.

We thank you for thinking about being a part of this important study.

Best wishes,  
Donna Pinto, Desiree Basila, Deborah Collyar, Liz Frank  
Patient Leadership Team of the COMET Study